Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 11/20 | 0.54 |
| ▸ | ACHE | P22303 | 11/20 | 0.54 |
| ▸ | BACE1 | P56817 | 11/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278559 | 0.87 | ACHE (0.67) | KDM4EGAABCHEACHEBACE1 | |
| SCHEMBL4649037 | 0.87 | ACHE (0.67) | KDM4EGAABCHEACHEBACE1 | |
| SCHEMBL4225304 | 0.81 | MCHR1 (0.54) | KDM4EGAASIGMAR1DRD2DRD4 | |
| SCHEMBL2279311 | 0.81 | KDM4E (0.66) | KDM4EGAABCHEACHEBACE1 | |
| SCHEMBL4229449 | 0.80 | SIGMAR1 (0.53) | KDM4EGAABCHEACHEBACE1 | |
| SCHEMBL4229453 | 0.80 | SIGMAR1 (0.53) | KDM4EGAABCHEACHEBACE1 | |
| SCHEMBL13419693 | 0.78 | KDM4E (0.74) | KDM4EGAABCHEACHEBACE1 | |
| SCHEMBL13419300 | 0.77 | GAA (0.72) | KDM4EGAABCHEACHEBACE1 | |
| Hydrochloric Acid SCHEMBL4232700 | 0.77 | CCR3 (0.54) | KDM4EGAABCHEACHESIGMAR1 | |
| Hydrochloric Acid SCHEMBL4232697 | 0.77 | CCR3 (0.54) | KDM4EGAABCHEACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | KDM4E 200/4885GAA 1351/4885BCHE 3123/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | KDM4E 195/4885GAA 1156/4885BCHE 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.